https://www.selleckchem.com/products/h2dcfda.html
Previous studies have shown seasonal variation in asthma exacerbations, peaking over the winter months. Asingle-inhaler triple therapy containing extrafine formulations of the inhaled corticosteroid (ICS) beclomethasone dipropionate (BDP), long-acting β -agonist formoterol fumarate (FF), and long-acting muscarinic antagonist glycopyrronium (G) is in development for asthma. We sought to evaluate whether calendar season impacted the relative effect of BDP/FF/G versus BDP/FF on moderate and severe asthma exacerbations. TRIMARAN and TRIGGER
Like
Comment
Share
